Ultrapure dialysate influences serum myeloperoxidase levels and lipid metabolism

Blood Purification

Volumn 28, Issue 1, 2009, Pages 29-39

  Honda, Hirokazu ^a   Suzuki, Hiroki ^a   Hosaka, Nozomu ^a   Hirai, Yuki ^a   Sanada, Daisuke ^a   Nakamura, Mari ^a   Nagai, Hisako ^a   Ashikaga, Eijin ^a   Matsumoto, Kei ^a   Mukai, Masanori ^a   Watanabe, Makoto ^a   Akizawa, Tadao ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Lipid abnormality; Oxidative stress; Ultrapure dialysate

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CELLULOSE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTOXIN; ERYTHROPOIETIN; IRON; LIPID; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; POLY(METHYL METHACRYLATE); POLYSULFONE; SEVELAMER;

ADULT; ANEMIA; ARTICLE; ARTIFICIAL KIDNEY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; COHORT ANALYSIS; CONTROLLED STUDY; DIALYSATE; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; FEMALE; FILTER; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERUM; ULTRAPURE DIALYSATE;

AGED; APOLIPOPROTEINS B; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; COHORT STUDIES; DIALYSIS SOLUTIONS; ENDOTOXINS; EQUIPMENT DESIGN; FEMALE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PEROXIDASE; RENAL DIALYSIS;

EID: 62949215586     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000210035     Document Type: Article

References (36)

1. Stenvinkel P, Pecoits-Filho R, Lindholm B:Coronary artery disease in end-stage renal disease:no longer a simple plumbing problem. J Am Soc Nephrol 2003; 14:1927-1939.
2. Kaysen GA:Association between inflammation and malnutrition as risk factors of car-diovascula r disease. Blood Purif 2006; 24:51-55.
3. Hoenich NA, Ronco C, Levin R:The importance of water quality and haemodialysis f lu-id composition. Blood Purif 2006; 24:11-18.
4. Stenvinkel P, Heimburger O, Paultre F, Dicz-falusy U, Wang T, Berglund L, Jogestrand T:Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55:1899-1911.
5. Lonnemann G:The quality of dialysate:an integrated approach. Kidney Int Suppl 2000; 76:S112-S119.
6. Ronco C, Bowry S, Tetta C:Dialysis patients and cardiovascular problems:can technology help solve the complex equation? Blood Purif 2006; 24:39-45.
7. Hoenich N, Thijssen S, Kitzler T, Levin R, Ronco C:Impact of water quality and dialysis fluid composition on dialysis practice. Blood Purif 2008; 26:6-11.
8. Hoenich NA, Ronco C:Haemodialysis fluid:composition and clinical importance. Blood Purif 2007; 25:62-68.
9. Masakane I:Review:clinical usefulness of ultrapure dialysate-recent evidence and perspect ives. Ther Apher Dial 2006; 10:348-354.
10. Bommer J, Jaber BL:Ultrapure dialysate:facts and myths. Semin Dial 2006; 19:115-119.
11. Izuhara Y, Miyata T, Saito K, Ishikawa N, Ka-kuta T, Nangaku M, Yoshida H, Saito A, Ku-rokawa K, van Ypersele de Strihou C:Ultra-pure dialysate decreases plasma pentosidine, a marker of 'carbonyl stress'. Am J Kidney Dis 2004; 43:1024-1029.
12. Shoji T, Nishizawa Y:Plasma lipoprotein abnormalities in hemodialysis patients-clinical implications and therapeutic guidelines. Ther Apher Dial 2006; 10:305-315.
13. Kalantar-Zadeh K, Brennan ML, Hazen SL:Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2006; 48:59-68.
14. Okubo K, Ikewaki K, Sakai S, Tada N, Kawa-guchi Y, Mochizuki S:Abnormal HDL apo-lipoprotein A-I and A-II kinetics in hemodi-alysis patients:a stable isotope study. J Am Soc Nephrol 2004; 15:1008-1015.
15. Ginsburg I:The role of bacteriolysis in the pathophysiology of inflammation, infection and post-infectious sequelae. APMIS 2002; 110:753-770.
16. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergstrom J:Factors predicting malnutrition in hemodialysis patients:a cross-sectional study. Kidney Int 1998; 53:773-782.
17. Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, Benazeth S, Cynober L, Aussel C:Geriatric nutritional risk index:a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr 2005; 82:777-783.
18. Yamada K, Fur uya R, Takita T, Maruyama Y, Yamaguchi Y, Ohkawa S, Kumagai H:Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr 2008; 87:106-113.
19. Daugirdas JT:Second generation logarithmic estimates of single-pool variable volume Kt/V:an analysis of error. J Am Soc Nephrol 1993; 4:1205-1213.
20. Shinzato T, Nakai S, Fujita Y, Takai I, Morita H, Nakane K, Maeda K:Determination of Kt/V and protein catabolic rate using pre-and postdialysis blood urea nitrogen concentrations. Nephron 1994; 67:280-290.
21. Tanaka S, Iwanaga S:Limulus test for detecting bacterial endotoxins. Methods Enzymol 1993; 223:358-364.
22. Kaysen GA, Levin NW, Mitch WE, Chapman AL, Kubala L, Eiserich JP:Evidence that C-reactive protein or IL-6 are not surrogates for all inflammatory cardiovascular risk factors in hemodialysis patients. Blood Purif 2006; 24:508-516.
23. Borawski J:Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress:the underestimated modifying effects of heparin. Am J Kidney Dis 2006; 47:37-41.
24. R iegel W, Leverenz K, Schollmeyer P, Wilms H, Horl WH:Plasma levels of main granulo-cyte components during hemodialysis:effects of immunosuppression. Nephron 1987; 46:161-166.
25. Wu CC, Chen JS, Wu WM, Liao TN, Chu P, Lin SH, Chuang CH, Lin YF:Myeloperoxi-dase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant 2005; 20:1134-1139.
26. Powell AK, Yates EA, Fernig DG, Turnbull JE:Interactions of heparin/heparan sulfate with proteins:appraisal of structural factors and experimental approaches. Glycobiology 2004; 14:17R-30R.
27. Prichard SS:Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003; 14:S315-S320.
28. Attman PO, Alaupovic P:Lipid and apolipo-protein profiles of uremic dyslipoprotein-emia-relation to renal function and dialysis. Nephron 1991; 57:401-410.
29. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H:Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialy-sis. Atherosclerosis 1997; 131:229-236.
30. Packard CJ, Saito Y:Non-hdl cholesterol as a measure of atherosclerotic risk. J Atheroscler Thromb 2004; 11:6-14.
31. Oi K, Hirano T, Sakai S, Kawaguchi Y, Ho-soya T:Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemo-dia lysis patients. K idney Int Suppl 1999; 71:S227-S228.
32. Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P:Lipo-protein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002; 61:209-218.
33. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group:K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41(suppl 3):I-IV, S1-S91.
34. Pennell P, Leclercq B, Delahunty MI, Walters BA:The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease. Clin Nephrol 2006; 66:336-347.
35. Thompson A, Danesh J:Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease:a literature-based meta-analy-sis of prospective studies. J Intern Med 2006; 259:481-492.
36. Desmeules S, Arcand-Bosse JF, Bergeron J, Douville P, Agharazii M:Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis 2005; 45:1067-1072.